DMARDs for Rheumatoid Arthritis – How They Work & What Patients Should Know

DMARDs (Disease-Modifying Anti-Rheumatic Drugs) are the foundation of Rheumatoid Arthritis treatment. They are not painkillers. They are not optional add-ons. They are the medications that slow or stop the disease itself.

This page explains what DMARDs are, how they work, why they are prescribed early, and what patients are often not told,  in clear, practical language.

What Are DMARDs?

DMARDs are medications that modify the immune response that drives RA.

They:

• reduce inflammation
• suppress abnormal immune activity
• prevent joint damage
• lower flare frequency
• improve long-term outcomes

Unlike pain relief, DMARDs change the course of the disease.

Why DMARDs Are Started Early

Early RA is a critical window.

Starting DMARDs early:

• reduces permanent joint damage
• improves long-term function
• increases chance of remission
• lowers disability risk

Delaying DMARDs –  or wanting to “wait and see” – can cause irreversible joint damage.  So consider carefully.

Common Conventional DMARDs Used in RA

Methotrexate

Methotrexate is usually the first DMARD your rheumatologist will prescribe, and there’s good reason for that, it works well for many people.

What it does:

• Suppresses the inflammatory immune pathways driving your RA
• Reduces synovitis (the inflamed joint lining)
• Makes biologics work better if you need to add one later

Key facts patients should know:

It’s taken once a week, not daily.

This trips people up occasionally. You take it on the same day each week (many people pick “Methotrexate Monday”), not every day like most medications.

It works gradually.

Don’t expect miracles in week one. Most people start noticing improvement around 6-8 weeks, with full benefits by 3-6 months.

Folic acid is your friend.

Taking folic acid (commonly daily, but skip your methotrexate day) significantly reduces side effects like nausea, mouth sores, and fatigue. If your doctor didn’t prescribe this with your methotrexate, ask for it.

Injectable methotrexate can be a game-changer.

If you’re struggling with nausea or other GI side effects from the pills, the subcutaneous injection often bypasses these problems entirely. It’s a tiny needle you do at home once a week—less scary than it sounds.

Methotrexate is not chemotherapy

About that “chemo” thing: Yes, methotrexate is used in much higher doses to treat certain cancers. But the dose you’re taking for RA is a fraction of chemotherapy doses…typically 10-25mg weekly versus 100-1000mg+ for cancer. At RA doses, methotrexate is NOT chemotherapy. It’s an immune modulator that’s been safely used for rheumatic diseases for over 40 years.

Methotrexate is one of the most studied medications in rheumatology and is very safe when properly monitored with regular blood tests.

Sulfasalazine

Sulfasalazine often flies under the radar, but it’s a solid DMARD option, frequently used alone in milder disease or as part of combination therapy.

What you should know:

• It’s particularly useful across different types of inflammatory arthritis (not just RA)
• Works more slowly but modifies disease over time
• Commonly used in “triple therapy” alongside methotrexate and hydroxychloroquine
• Can cause some GI upset initially, but often improves as your body adjusts
• Requires monitoring, but generally well-tolerated

Some people do really well on sulfasalazine, especially in combination with other DMARDs. It’s been around since the 1940s and has a long track record of safety and effectiveness.

Hydroxychloroquine (Plaquenil)

Hydroxychloroquine is often considered a weaker DMARD, but that’s not always the case.  Its very commonly used in Lupus, and many people who have RA have a ‘crossover syndrome’, meaning they have symptoms of lupus, but don’t meat the diagnostic criteria.

What it does:

• Provides mild to moderate immune modulation
• Has a lower side-effect burden than many other DMARDs
• Works well for early or milder disease
• Often combined with methotrexate for additional benefit

Why it matters:  For some people with milder disease or early RA, it provides adequate control with minimal side effects. For others, it’s an excellent addition to methotrexate when one drug alone isn’t quite enough.

The main monitoring requirement is annual eye exams to check for rare retinal changes, a small inconvenience for a medication that many people tolerate extremely well.

Leflunomide (Arava)

Leflunomide is often the go-to alternative when methotrexate isn’t an option, whether because of side effects, liver issues, or other contraindications.

What it does:

• Suppresses the proliferation of overactive immune cells
• Has a long half-life, meaning it stays in your system (which matters if you need to stop it)
• Requires regular monitoring like other DMARDs

Key considerations:

The good:

Many people who can’t tolerate methotrexate do well on leflunomide. It’s effective, once-daily, and doesn’t require weekly dosing coordination.

The tricky part:

Because it has a long half-life (stays in your body for weeks to months), if you need to stop it quickly, say, if you want to get pregnant or develop side effects, there’s a washout procedure using cholestyramine to clear it from your system faster.

If you’re planning pregnancy in the near future, discuss this with your rheumatologist, as leflunomide requires stopping well in advance (unlike some other DMARDs).

Combination DMARD Therapy

Many patients require more than one DMARD to adequately control their disease.

Combination therapy can:

• improve disease control
• reduce flares
• delay or prevent the need for biologics in some cases

Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) is a well-established combination that has shown comparable effectiveness to some biologics in clinical trials. However, tolerating three medications simultaneously can be challenging, and side effects may be significant.

Common starting approaches:

• Moderate to severe disease: Methotrexate is typically the first-line DMARD, sometimes combined with other conventional DMARDs or escalated to biologics if response is inadequate
• Mild disease: Hydroxychloroquine (Plaquenil) is often used as initial monotherapy due to its favourable safety profile

The choice between monotherapy, combination conventional DMARDs, or early biologic use depends on disease severity, prognostic factors (such as high antibody levels or early erosions), and individual patient factors including comorbidities and tolerability.

How Long Do DMARDs Take to Work?

DMARDs aren’t quick fixes, they work slowly to modify your disease over time.

Most people start noticing some improvement around 6–8 weeks, but it typically takes 3–6 months to feel the full benefit. Think of it like planting a tree: you won’t see results overnight, but the wait is worth it.

Because of this lag time, your rheumatologist might prescribe steroids or other short-term treatments to help manage your symptoms and reduce flares, while you’re waiting for the DMARD to kick in. This is sometimes called “bridge therapy”, it gets you through until the real work begins.

The key is patience (easier said than done when you’re in pain, I know). If you’re not seeing any improvement by 3 months, that’s when you should have a conversation with your doctor about adjusting your treatment plan.

Side Effects: Separating Facts from Fear

Let’s be real: all medications come with risks, and DMARDs are no exception. But if you’ve spent time in online patient groups, you’ve probably encountered some truly alarming stories that can make these medications sound terrifying.

Here’s the thing:  people having good experiences are usually out living their lives, not posting daily updates. Meanwhile, the relatively small number of people who have serious reactions (which are real and valid) tend to be more visible online. This creates a skewed picture that can make serious side effects seem far more common than they actually are.

What most people actually experience:

Many people tolerate DMARDs well. When side effects do occur, they’re usually manageable and not serious, including:

• Nausea (with methotrexate, this often improves with folic acid or by splitting doses)
• Fatigue on dosing day
• Mild hair thinning
• Occasional mouth ulcers

What doctors monitor for (less common, but important):

• Liver enzyme elevations
• Changes in blood counts
• Lung reactions (rare, but caught early through monitoring)

Here’s what matters: You’ll have regular blood tests specifically designed to catch potential problems before they cause harm. Your rheumatologist isn’t just prescribing and hoping for the best, there’s a whole monitoring system in place.

Should you be aware of risks? Absolutely. Should you let worst-case scenarios from internet strangers stop you from treating active disease?  Absolutely not!  Untreated inflammatory disease has its own very real risks: joint damage, disability, and systemic complications.

Talk to your doctor about your specific risk factors, not someone else’s experience from a Facebook group.  And remember, all of these side effects are reversable, when caught early.  So keep up the blood work and monitoring that your rheumatologist prescribes.

Why Methotrexate Gets Such a Bad Rap (And Why That’s a Problem)

Methotrexate is the gold standard, cornerstone treatment for rheumatoid arthritis. It’s the most commonly prescribed DMARD, and for good reason.  Decades of research support its effectiveness and safety at RA doses.

Yet if you Google it or ask in patient groups, you’ll find people calling it “chemo” and swapping horror stories that might make you want to flush your prescription down the toilet.

So what’s going on?

The fear largely comes from:

• Misinformation online – scary anecdotes spread faster than balanced experiences
• Confusing cancer dosing with RA dosing – cancer patients take much higher doses (often daily), while RA patients typically take a once-weekly dose that’s a fraction of chemotherapy amounts
• Lack of clear explanation from doctors – when your rheumatologist hands you a prescription without addressing the “but isn’t this chemo?” question, it’s natural to panic and turn to Google
• Dismissal of patient concerns – when legitimate questions are brushed off rather than answered, trust erodes and fear fills the gap

Here’s the reality: This fear leads to undertreatment, not safety.

Leaving RA untreated or undertreated is far more dangerous than trialling methotrexate. Unchecked inflammation damages joints, increases cardiovascular risk, and can affect your lungs, eyes, and other organs. Methotrexate, at RA doses with proper monitoring, has a well-established safety profile spanning decades of use.

Yes, methotrexate has side effects. Yes, some people don’t tolerate it well. But the risk-benefit equation for most people with active RA strongly favours treatment.

DMARDs vs Biologics

Here’s the current treatment landscape:

Conventional DMARDs (like methotrexate, sulfasalazine, hydroxychloroquine):

• Are first-line treatment – methotrexate monotherapy is now strongly recommended as the initial treatment for moderate to high disease activity PubMed
• Are mostly oral (though subcutaneous methotrexate is often better tolerated)
• Are significantly less expensive
• Have decades of safety data

Biologics and JAK inhibitors:

• Are targeted therapies that block specific immune pathways
• Are injectable or infused (though JAK inhibitors are oral)
• Cost thousands of dollars per month
• Are reserved for when conventional DMARDs don’t provide adequate control PubMed

So do you still have to “earn” your biologic?

In short: yes, but the barriers have been easing. In both the US and Australia, conventional DMARDs remain first-line treatment, with biologics typically initiated when there’s ongoing active disease or poor prognostic factors despite conventional therapy Medscape.

In Australia specifically, biologics are PBS-subsidized only for “severe active rheumatoid arthritis,” and you must meet specific eligibility criteria Everyone.org to access them. This generally means demonstrating that conventional DMARDs haven’t worked well enough. The good news is that the approval process has been streamlined All-imm in recent years to reduce administrative burden.

What about triple therapy?

The guidelines have shifted somewhat. Current ACR guidelines actually prefer methotrexate plus a biologic over triple therapy, mainly because it’s faster-acting PubMed. That said, triple therapy is still used and remains a valid option, particularly when biologics aren’t accessible or appropriate.

The bottom line: Conventional DMARDs aren’t outdated, they’re foundational. Yes, biologics are powerful and sometimes necessary, but they’re expensive, require monitoring, and come with their own risks. Starting with methotrexate makes sense for most people, and many achieve excellent control without ever needing a biologic.

Internal link: Biologics for RA (future)

When DMARDs Aren’t Enough

Sometimes conventional DMARDs just don’t get you where you need to be. Signs it might be time to escalate treatment:

• Persistent pain and swelling despite treatment
• Frequent flares that disrupt your life
• Rising inflammatory markers on bloodwork
• Declining function…things you could do before are getting harder

If you’re experiencing these, it’s a sign that its time to escalate to a biologic or add another medication.  This isn’t “over-treatment”, it’s appropriate care. The goal is remission or low disease activity, and if you’re not there, your treatment plan should adjust accordingly.

Don’t let anyone make you feel like you’re asking for too much by wanting to actually feel better.

DMARDs and Quality of Life

When DMARDs work well, the changes can be profound. People often describe:

• Waking up without that crushing morning stiffness
• Having energy to actually do things after work or returning to work after being unable to
• Being able to exercise again (or start for the first time)
• Flares becoming rare instead of constant
• Keeping up with daily life without help

There’s a quote that comes up again and again from patients who find the right treatment: “I didn’t realize how bad I felt until I felt better.”

It’s easy to adjust to a new normal where pain and exhaustion are just part of life. You might not even realize how much you’ve been compensating—until suddenly you’re not anymore. That’s what good RA treatment can do: give you back the version of yourself you’d forgotten was possible.

The Bottom Line

DMARDs aren’t just about feeling better today—they’re about protecting your future. Here’s what matters:

• They treat the underlying disease process, not just mask symptoms
• They prevent irreversible joint damage and disability
• They’re safer than letting inflammation run wild through your body
• They deserve clear explanation, not fearmongering

If your RA pain persists despite treatment, you probably need more medication, not less.

I know that’s not what anyone wants to hear. Adding another pill or injection to your routine isn’t pleasant. But here’s the reality: moderate to severe RA doesn’t respond to wishful thinking, diet changes, or supplements alone. Those things might help you feel somewhat better, but they won’t stop the inflammatory process that’s actively damaging your joints.

Untreated or undertreated RA leads to:

• Progressive joint destruction that can’t be reversed
• Permanent disability
• Increased cardiovascular risk
• Systemic complications affecting your lungs, eyes, and other organs

Medication is essential because it’s the only thing proven to actually halt this damage. Yes, living well with RA includes stress management, gentle exercise, good nutrition, and adequate rest—but these are complements to medication, not substitutes for it. The anti-inflammatory diet isn’t going to stop your immune system from attacking your joints. Only targeted medical treatment can do that.

Better disease control isn’t about over-medicating—it’s about giving yourself the best shot at preserving your quality of life and independence for decades to come.

FAQ

Primary source:

• NEJM 2013 study – “Therapies for Active Rheumatoid Arthritis after Methotrexate Failure” New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa1303006
  • This was a 48-week, double-blind, noninferiority trial comparing triple therapy (MTX + sulfasalazine + hydroxychloroquine) to etanercept + methotrexate
  • Result: Triple therapy was noninferior to etanercept plus methotrexate New England Journal of Medicine

Additional supporting studies:

• The TEAR trial (Treatment of Early Aggressive Rheumatoid Arthritis) is another major study https://pmc.ncbi.nlm.nih.gov/articles/PMC4036119/
• Cochrane network meta-analysis (2016) comparing multiple DMARD combinations Reference: Hazlewood et al., Cochrane Database Syst Rev. 2016